Tumor Biology and Metastasis

Withrow and MacEwen's Small Animal Clinical Oncology

Volumn , Issue , 2006, Pages 31-53

  Argyle, David J ^a,b   Khanna, Chand ^c,d,e  

^a RCVS and European Specialist in Veterinary Oncology   (Germany)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Friendship Hospital for Animals   (United States)

^e Nutrition and Policy Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45949112566     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-072160558-6.50005-8     Document Type: Chapter

References (145)

1. McCance KL, Roberts LK Cellular biology. Pathophysiology: the biological basis of disease in adults and children 1997, Mosby, St. Louis. ed 3. K.L. McCance, S.E. Huether (Eds.).
2. Wyke J Viruses and cancer. The molecular and cellular biology of cancer 1997, Oxford University Press, New York. ed 3. T. Franks (Ed.).
3. Vousden KH Cell transformation by human papillomaviruses. Viruses and cancer 1994, Cambridge University Press, Cambridge, UK. Minsen (Ed.).
4. Campo MS, O'Neil BW, Barron RJ, et al. Experimental reproduction of the papilloma-carcinoma complex of the alimentary canal in cattle. Carcinogenesis 1994, 8:1597-1601.
5. Campo MS, Jarrett WF, Barron R, et al. Association of bovine papillomavirus type 2 and bracken fern with bladder cancer in cattle. Cancer Res 1992, 52:6898-6904.
6. Donner P, Greiser-Wilkie I, Moelling K Nuclear localization and DNA binding of the transforming gene product of avian myelocyomatosis virus. Nature 1982, 296:262-266.
7. Reid SW, Smith KT, Jarrett WF Detection, cloning and characterisation of papillomaviral DNA present in sarcoid tumours of Equus asinus. Vet Rec 1994, 135:430-432.
8. Gaukroger JM, Bradley A, Chandrachud L, et al. Interaction between bovine papillomavirus type 4 and cocarcinogens in the production of malignant tumours. J Gen Virol 1993, 74(Pt 10):2275-2280.
9. Jarrett WF Bovine papilloma viruses. Clin Dermatol 1985, 3:8-19.
10. Lancaster WD, Olson C, Meinke W Bovine papillomavirus: presence of virus-specific DNA sequences in naturally occurring equine tumours. Proc Natl Acad Sci USA 1977, 74:524-528.
11. Golias CH, Charalabopoulos A, Charalabopoulos K Cell proliferation and cell cycle control: a mini review. Intl J Clinical Prac 2004, 58:1134-1141.
12. Kong N, Fotouhi N, Wovkulich PM, et al. Cell cycle inhibitors for the treatment of cancer. Drugs of the Future 2003, 28:881-896.
13. Lane DP P53: guardian of the genome. Nature 1992, 358:15-16.
14. Levine AJ p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
15. Wu X, Bayle JH, Olson D, et al. The p53-mdm2 autoregulatory loop. Genes & Development 1993, 7:1126-1132.
16. Haupt Y, Maya R, Kazaz A, Oren M Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
17. Wyllie AH, Kerr JF, Currie AR Cell death: the significance of apoptosis. Int Rev Cytol 1980, 68:251-306.
18. Evan G, Littlewood T A matter of life and cell death. Science 1998, 281:1317-1322.
19. McCance KL, Roberts LK The biology of cancer. Pathophysiology: the biological basis of disease in adults and children 1997, Mosby, St. Louis. ed 3. K.L. McCance, S.E. Huether (Eds.).
20. Jarrett O, Onions D Leukaemogenic viruses. Leukaemia 1992, Blackwells Scientific, Oxford. J.A. Whittaker (Ed.).
21. Balmain A, Brown K Oncogene activation in chemical carcinogenesis. Adv Cancer Research 1988, 51:147-182.
22. Adams GE, Cox R Radiation carcinogenesis. The molecular and cellular biology of cancer 1997, Oxford University Press, New York. ed 3. L.M. Franks, N.M. Teich (Eds.).
23. Neil JC, Hughs D, McFarlane R, et al. Transduction and rearrangement of the myc gene by feline leukaemia virus in naturally occurring T cell leukemias. Nature 1984, 308:814-820.
24. Onions DE, Lees G, Forrest D, et al. Recombinant feline viruses containing the myc gene rapidly produce clonal tumours expressing T-cell antigen receptor gene transcripts. Intl J Cancer 1987, 40:40-45.
25. Teich N Oncogenes and cancer. The molecular and cellular biology of cancer 1997, Oxford University Press, New York. ed 3. F. Teich (Ed.).
26. Tennent R, Wigley C, Balmain A Chemical carcinogenesis. The molecular and cellular biology of cancer 1997, Oxford University Press, New York, . ed 3. T. Franks (Ed.).
27. Huret JL, Senon S, Bernheim A, et al. An atlas on genes and chromosomes in oncology and haematology. Cellular Molecular Biol 2004, 50:805-807.
28. Soto AM, Sonnenschein C The somatic mutation theory of cancer: growing problems with the paradigm?. Bioessays 2004, 26:1097-1107.
29. Griffey SM, Kraegel SA, Weller RE, et al. K-ras mutations in 239PuO2 canine lung neoplasms. Cancer Lett 1998, 132:1-5.
30. Mayr B, Schaffner G, Reifinger M K-ras mutations in canine pancreatic cancers. Vet Rec 2003, 153:87-89.
31. Downing S, Chien MB, Kass PH, et al. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002, 63:1718-1723.
32. Knudson AG Mutations and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823.
33. Weinberg RA The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
34. Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 1992, 358:80-83.
35. Vogelstein B, Kinzler KW p53 function and dysfunction. Cell 1992, 70:525-526.
36. Sluss HK, Jones SN Analysing p53 tumour suppressor functions in mice. Expert Opinion on Therapeutic Targets 2003, 7:89-99.
37. Harris CC p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996, 17:1187-1198.
38. Nasir L, Rutteman GR, Reid SW, et al. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas. Cancer Lett 2001, 174:83-89.
39. Nasir L, Burr P, Mcfarlane S, et al. Cloning, sequence analysis and expression of the cDNA's encoding the canine and equine homologues of the mouse double minute two proto-oncogene. Cancer Lett 2000, 152:9-13.
40. Nasir L, Krasner H, Argyle DJ, et al. A study of p53 tumour suppressor gene immunoreactivity in feline neoplasia. Cancer Lett 2000, 155:1-7.
41. Nasir L, Argyle DJ Mutational analysis of p53 in two cases of bull mastiff lymphosarcoma. The Vet Record 1999, 145:23-24.
42. Nasir L, Argyle DJ, McFarlane ST, et al. Nucleotide sequence of a highly conserved region of the canine p53 tumour suppressor gene. DNA Sequence 1998, 8:83-86.
43. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000, 100:57-70.
44. Blasco MA, Funk W, Villeponteau B, et al. Functional characterization and developmental regulation of mouse telomerase RNA. Science 1995, 269:1267-1270.
45. Blasco MA, Lee H-W, Hande MP, et al. Telomere shortening and tumour formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
46. Hayflick L Mortality and immortality at the cellular level: a review. Biochemistry 1997, 62:1180-1190.
47. Biller BJ, Kitchel B, Casey D, et al. Evaluation of an assay for detecting telomerase activity in neoplastic tissues of dogs. Amer J Vet Research 1998, 59:1526-1528.
48. McKenzie K, Umbricht CB, Sukumar S Applications of telomerase research in the fight against cancer. Molecular Medicine Today 1999, (March):114-122.
49. Nasir L, Devlin P, Mckevitt T, Rutteman G, et al. Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. Neoplasia 2001, 3:351-359.
50. Shay JW, Wright WE Telomerase activity in human cancer. Curr Opin in Oncology 1996, 8:66-71.
51. Yazawa M, Okuda M, Setoguchi A, et al. Measurement of telomerase activity in dog tumours. J Vet Med Sci 1999, 61:1125-1129.
52. Zhu J, Wang H, Bishop JM, et al. Telomerase extends the life-span of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci USA 1999, 96:3723-3728.
53. Sell S Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004, 51:1-28.
54. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
55. Clark EA, Golub TR, Lander ES, et al. Genomic analysis of metastasis reveals an essential role for RhoC [in process citation]. Nature 2000, 406:532-535.
56. Shevde LA, Welch DR Metastasis suppressor pathways-an evolving paradigm. Cancer Lett 2003, 198:1-20.
57. Steeg PS, Ouatas T, Halverson D, et al. Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer 2003, 4:51-62.
58. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004, 10:182-186.
59. Liotta LA, Kohn EC The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
60. Condeelis J, Segall JE Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003, 3:921-930.
61. Wang W, Wyckoff JB, Frohlich VC, et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res 2002, 62:6278-6288.
62. Wyckoff JB, Segall JE, Condeelis JS The collection of the motile population of cells from a living tumor. Cancer Res 2000, 60:5401-5404.
63. Jankowski MK, Ogilvie GK, Lana SE, et al. Matrix metalloproteinase activity in tumor, stromal tissue, and serum from cats with malignancies. J Vet Intern Med 2002, 16:105-108.
64. Hirayama K, Yokota H, Onai R, et al. Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. J Comp Pathol 2002, 127:249-256.
65. Leibman NF, Lana SE, Hansen RA, et al. Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. J Vet Intern Med 2000, 14:583-586.
66. Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 2000, 61:111-114.
67. Loukopoulos P, Mungall BA, Straw RC, et al. Matrix metalloproteinase-2 and -9 involvement in canine tumors. Vet Pathol 2003, 40:382-394.
68. Coussens LM, Fingleton B, Matrisian LM Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
69. Mook OR, Frederiks WM, Van Noorden CJ The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004, 1705:69-89.
70. Ramnath N, Creaven PJ Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004, 6:96-102.
71. Hendrix MJ, Seftor EA, Hess AR, et al. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003, 3:411-421.
72. Kalluri R Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003, 3:422-433.
73. Frisch SM, Francis H Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994, 124:619-626.
74. Grossmann J Molecular mechanisms of "detachment-induced apoptosis-Anoikis,". Apoptosis 2002, 7:247-260.
75. Marco RA, Diaz-Montero CM, Wygant JN, et al. Alpha 4 integrin increases anoikis of human osteosarcoma cells. J Cell Biochem 2003, 88:103810-103847.
76. Cavallaro U, Christofori G Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann NY Acad Sci 2004, 1014:58-66.
77. Guo W, Giancotti FG Integrin signaling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826.
78. Akhtar N, Padilla ML, Dickerson EB, et al. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004, 6:106-116.
79. Moore PF, Schrenzel MD, Affolter VK, et al. Canine cutaneous histiocytoma is an epidermotropic Langerhans cell histiocytosis that expresses CD1 and specific beta 2-integrin molecules. Am J Pathol 1996, 148:1699-1708.
80. Restucci B, De Vico G, Maiolino P Expression of beta 1 integrin in normal, dysplastic and neoplastic canine mammary gland. J Comp Pathol 1995, 113:165-173.
81. Olivry T, Moore PF, Naydan DK, et al. Investigation of epidermotropism in canine mycosis fungoides: expression of intercellular adhesion molecule-1 (ICAM-1) and beta-2 integrins. Arch Dermatol Res 1995, 287:186-192.
82. Moore PF, Rossitto PV, Danilenko DM Canine leukocyte integrins: characterization of a CD18 homologue. Tissue Antigens 1990, 36:211-220.
83. Fukata M, Kaibuchi K Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat Rev Mol Cell Biol 2001, 2:887-897.
84. Ruoslahti E, Reed JC Anchorage dependence, integrins, and apoptosis. Cell 1994, 77:477-478.
85. Duxbury MS, Ito H, Zinner MJ, et al. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 2004, 135:555-562.
86. Douma S, Van Laar T, Zevenhoven J, et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430:1034-1039.
87. Valentijn AJ, Zouq N, Gilmore AP Anoikis. Biochem Soc Trans 2004, 32:421-425.
88. Takenaka Y, Fukumori T, Raz A Galectin-3 and metastasis. Glycoconj J 2004, 19:543-549.
89. Dalgleish A, Whelan M Novel immunotherapeutic approaches to prostate cancer. Curr Opin Mol Ther 2005, 7:30-34.
90. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998, 95:7556-7561.
91. Lascelles BDX, Dernell WS, Correa MT, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Annals Surg Oncol 2005, 12:1073-1083.
92. Markiewicz MA, Kast WM Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest 2004, 22:417-434.
93. Mocellin S, Mandruzzato S, Bronte V, et al. Part I: Vaccines for solid tumours. Lancet Oncol 2004, 5:681-689.
94. Elmslie RE, Dow SW Genetic immunotherapy for cancer. Semin Vet Med Surg (Small Anim) 1997, 12:193-205.
95. Kurzman ID, MacEwen EG, Rosenthal RC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995, 1:1595-1601.
96. Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995, 1:1165-1170.
97. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003, 9:1284-1290.
98. Yannelli JR, Wroblewski JM On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 2004, 23:97-113.
99. Bagge U, Skolnik G, Ericson LE The arrest of circulating tumor cells in the liver microcirculation: s vital fluorescence microscopic, electron microscopic and isotope study in the rat. J Cancer Res Clin Oncol 1983, 105:134-140.
100. Chambers AF, MacDonald IC, Schmidt EE, et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995, 14:279-301.
101. Chambers AF, Naumov GN, Vantyghem SA, et al. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res 2000, 2:400-4047.
102. Chambers AF, Naumov GN, Varghese HJ, et al. Critical steps in hematogenous metastasis: an overview. Surg Oncol Clin N Am 2001, 10:243-255. vii.
103. Chambers AF, Schmidt EE, MacDonald IC, et al. Early steps in hematogenous metastasis of B16F1 melanoma cells in chick embryos studied by high-resolution intravital videomicroscopy. J Natl Cancer Inst 1992, 84:797-803.
104. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997, 15:796-807.
105. Wang H, Fu W, Im JH, et al. Tumor cell αβ 1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 2004, 164:935-941.
106. Groom AC, MacDonald IC, Schmidt EE, et al. Tumour metastasis to the liver, and the roles of proteinases and adhesion molecules: new concepts from in vivo videomicroscopy. Can J Gastroenterol 1999, 13:733-743.
107. Goodison S, Urquidi V, Tarin D CD44 cell adhesion molecules. Mol Pathol 1999, 52:189-196.
108. Martin TA, Harrison G, Mansel RE, et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003, 46:165-186.
109. Al-Mehdi AB, Tozawa K, Fisher AB, et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 2000, 6:100-102.
110. Cooper CR, Chay CH, Gendernalik JD, et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003, 97(3 Suppl):739-747.
111. De Wever O, Mareel M Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200:429-447.
112. Mueller MM, Fusenig NE Friends or foes: bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
113. Bagnato A, Natali PG Targeting endothelin axis in cancer. Cancer Treat Res 2004, 119:293-314.
114. Guise TA, Mohammad KS Endothelins in bone cancer metastases. Cancer Treat Res 2004, 118:197-212.
115. Guise TA, Yin JJ, Mohammad KS Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003, 97(3 Suppl):779-784.
116. Nelson JB Endothelin inhibition: novel therapy for prostate cancer. J Urol 2003, 170(6 Pt 2):S65-S67. discussion S7-S8.
117. Kerbel RS Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21:505-515.
118. Alani RM, Silverthorn CF, Orosz K Tumor angiogenesis in mice and men. Cancer Biol Ther 2004, 3:498-500.
119. Kerbel RS Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2003, 2(4 Suppl 1):S134-S139.
120. Miller JC, Pien HH, Sahani D, et al. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005, 97:172-187.
121. Folkman J Endogenous angiogenesis inhibitors. Apmis 2004, 112:496-507.
122. Reiher FK, Volpert OV, Jimenez B, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002, 98:682-689.
123. Jain RK Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
124. Fidler I Modulation of the organ microenvironment for treatment of cancer metastais. J Natl Cancer Institute 1997.
125. Fidler IJ Critical determinants of metastasis. Semin Cancer Biol 2002, 12:89-96.
126. Fidler IJ The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003, 3:453-458.
127. Hunter KW Host genetics and tumour metastasis. Br J Cancer 2004, 90:752-755.
128. Hunter K, Welch DR, Liu ET Genetic background is an important determinant of metastatic potential. Nat Genet 2003, 34:23-24. author reply 25.
129. Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998, 153:865-873.
130. Loberg RD, Fridman Y, Pienta BA, et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia 2004, 6:302-309.
131. Butler TP, Gullino PM Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 1975, 35:512-516.
132. Chambers AF, MacDonald IC, Schmidt EE, et al. Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy. Cancer Metastasis Rev 1998, 17:263-269.
133. Barnhill RL The biology of melanoma micrometastases. Recent Results Cancer Res 2001, 158:313.
134. MacDonald IC, Groom AC, Chambers AF Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays 2002, 24:885-893.
135. Macaluso M, Paggi MG, Giordano A Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 2003, 22:6472-6478.
136. Charames GS, Bapat B Genomic instability and cancer. Curr Molecular Med 2003, 3:589-596.
137. Reya T, et al. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
138. Muhammad A, et al. Prospective identification of tumorigenic breast cancer cells. PNAS 2003, 100:3983-3988.
139. Muhammad A, et al. Self-renewal and solid tumor stem cells. Oncogene 2004, 23:7274-7282.
140. Dick J Breast cancer stem cells revealed. PNAS 2003, 100:3547-3549.
141. Keith WN From stem cells to cancer: balancing immortality and neoplasia. Oncogene 2004, 23:5092-5094.
142. Scadden: Cancer stem cells refined. Nature Immunology 2004, 5:701-703.
143. Muhammad A, et al. Therapeutic implications of cancer stem cells. Curr Opin in Genetics and Development 2004, 14:43-47.
144. Onions DE A prospective study of familial canine lymphosarcoma. J Natl Cancer Institute 1984, 72:909-912.
145. Veldhoen N, Stewart J, Brown R, et al. Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene 1998, 16:249-255.